PMID- 31929600
OWN - NLM
STAT- MEDLINE
DCOM- 20200415
LR  - 20200415
IS  - 1932-6203 (Electronic)
IS  - 1932-6203 (Linking)
VI  - 15
IP  - 1
DP  - 2020
TI  - Predictive factors of first dosage intravenous immunoglobulin-related adverse 
      effects in children.
PG  - e0227796
LID - 10.1371/journal.pone.0227796 [doi]
LID - e0227796
AB  - BACKGROUND: Intravenous immunoglobulin (IVIG) therapy is used in the treatment of 
      various diseases, and IVIG-related adverse effects (IVIG-AEs) vary from mild to 
      severe. However, the mechanisms underlying IVIG-AEs and the potential predictive 
      factors are not clear. This study investigated whether certain IVIG-AEs can be 
      predicted before IVIG administration. STUDY DESIGN AND METHODS: This 
      retrospective cohort study at the Division of Neurology, Saitama Children's 
      Medical Center included patients enrolled from 2008 to 2018 who were < 18 years 
      old and received IVIG for the first time. IVIG-AEs were classified according to 
      the Common Terminology Criteria for Adverse Events version 5.0. RESULTS: A total 
      of 104 patients fulfilled the inclusion criteria. The rate of IVIG-AEs was 37.5% 
      (39/104). The most frequent IVIG-AEs were fever (41.0% [16/39]) and headache 
      (38.5% [15/39]). AEs were below grade 2 in all except one patient and there were 
      no grade 4 AEs. High serum total protein (TP) level was significantly related to 
      the occurrence of IVIG-AEs (odds ratio, 14.8; 95% confidence interval, 2.4-90.5; 
      P < 0.01). The optimal cutoff TP level was 6.7 g/dL. Although low WBC count and 
      immunoglobulin G level may be predictive risk factors of IVIG-AEs, it was not 
      confirmed in this study. CONCLUSION: IVIG-AEs occurred in 37.5% of cases, and 
      most were mild. TP was the best predictive risk factor of IVIG-AEs before IVIG 
      administration. These results may aid in elucidating the mechanism underlying 
      IVIG-AEs.
FAU - Kubota, Jun
AU  - Kubota J
AUID- ORCID: 0000-0002-1891-4746
AD  - Division of Neurology, Saitama Children's Medical Center, Saitama, Japan.
AD  - Department of Pediatrics, The Jikei University School of Medicine, Tokyo, Japan.
FAU - Hamano, Shin-Ichiro
AU  - Hamano SI
AD  - Division of Neurology, Saitama Children's Medical Center, Saitama, Japan.
AD  - Department for Child Health and Human Development, Saitama Children's Medical 
      Center, Saitama, Japan.
FAU - Daida, Atsuro
AU  - Daida A
AD  - Division of Neurology, Saitama Children's Medical Center, Saitama, Japan.
FAU - Hiwatari, Erika
AU  - Hiwatari E
AD  - Division of Neurology, Saitama Children's Medical Center, Saitama, Japan.
AD  - Department of Pediatrics, The Jikei University School of Medicine, Tokyo, Japan.
FAU - Ikemoto, Satoru
AU  - Ikemoto S
AD  - Department for Child Health and Human Development, Saitama Children's Medical 
      Center, Saitama, Japan.
FAU - Hirata, Yuko
AU  - Hirata Y
AD  - Division of Neurology, Saitama Children's Medical Center, Saitama, Japan.
FAU - Matsuura, Ryuki
AU  - Matsuura R
AD  - Division of Neurology, Saitama Children's Medical Center, Saitama, Japan.
FAU - Hirano, Daishi
AU  - Hirano D
AD  - Department of Pediatrics, The Jikei University School of Medicine, Tokyo, Japan.
LA  - eng
PT  - Journal Article
DEP - 20200113
PL  - United States
TA  - PLoS One
JT  - PloS one
JID - 101285081
RN  - 0 (Immunoglobulins, Intravenous)
SB  - IM
MH  - Child
MH  - Child, Preschool
MH  - Exanthema/chemically induced
MH  - Female
MH  - Fever/chemically induced
MH  - Headache/chemically induced
MH  - Humans
MH  - Immunoglobulins, Intravenous/administration & dosage/*adverse effects
MH  - Incidence
MH  - Infant
MH  - Male
MH  - Nausea/chemically induced
MH  - Protective Factors
MH  - Retrospective Studies
MH  - Vomiting/chemically induced
PMC - PMC6957294
COIS- The authors have declared that no competing interest exist.
EDAT- 2020/01/14 06:00
MHDA- 2020/04/16 06:00
PMCR- 2020/01/13
CRDT- 2020/01/14 06:00
PHST- 2019/08/29 00:00 [received]
PHST- 2019/12/29 00:00 [accepted]
PHST- 2020/01/14 06:00 [entrez]
PHST- 2020/01/14 06:00 [pubmed]
PHST- 2020/04/16 06:00 [medline]
PHST- 2020/01/13 00:00 [pmc-release]
AID - PONE-D-19-24367 [pii]
AID - 10.1371/journal.pone.0227796 [doi]
PST - epublish
SO  - PLoS One. 2020 Jan 13;15(1):e0227796. doi: 10.1371/journal.pone.0227796. 
      eCollection 2020.